
Loneliness Is Inflaming Our Bodies—And Our Politics
In The Origins of Totalitarianism,Arendtemphasized one primary factor in the rise of authoritarianism that has little obvious connection to politics: loneliness. While we usually think of loneliness as not having our social needs met, Arendt defined the word as something deeper. Loneliness happens when there are no shared objective facts and no potential collective action to solve shared challenges. It's a state of being where you can't trust others. Loneliness, in Arendt's telling, inflames the connective tissues of a society. It weakens the body politic so that demagogues and despots can prey. 'What prepares men for totalitarian domination,' she wrote, '… is the fact that loneliness, once a borderline experience usually suffered in certain marginal social conditions like old age, has become an everyday experience.'
Arendt—as far as I know—didn't use the word 'inflammation' to describe the effects of social isolation on a country or culture. But it's the metaphor that, to me, gets to the essence of her warning.
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
Inflammation is the body's response to a sense of threat—a protective, contractionary response that can extend even to the cellular level. It's a response that can inhibit healing. A community or society that faces a deficit of meaningful connectedness is similarly in a state of perpetual threat; people are unable to listen to one another, to trust each other, to maintain trust in shared institutions, or to collectively overcome divisions.
This might sound familiar.
From 2003 to 2022, face-to-face socializing among U.S. men fell by 30 percent. For teenagers, it was a staggering 45 percent. An estimated 12 percent of Americans report having no close friends, a fourfold increase since 1990. While social media was supposed to amplify human connection, the rise of comparison culture, social sorting into echo chambers and the rapid decline of in-person social connection have instead coincided with unprecedented levels of anxiety, depression and distrust.
It should therefore come as no surprise that, in America, we're seeing democratic backsliding like Hannah Arendt warned of—including mass polarization, intentional disinformation and a politics of fear, retribution and rage.
Loneliness inflames societies.
It just so happens that loneliness inflames the body, too.
Two decades ago, researchers Louise Hawkley and John Cacioppo at the University of Chicago demonstrated in a landmark study that loneliness acts as a chronic stressor that triggers the body's innate stress-response systems. Social isolation keeps the hypothalamic-pituitary-adrenal (HPA) axis in a constant state of arousal, driving persistent cortisol release. This hormonal imbalance heightens inflammation. And this can, in turn, weaken the immune system, compromise cardiovascular health and worsen vulnerability to mental health conditions such as depression and anxiety. In short, the absence of meaningful social bonds can literally recalibrate the body's physiological mechanisms toward greater stress and illness.
Over the past two decades, further studies have only reinforced the link between loneliness and inflammatory pathways. George Slavich of the University of California, Los Angeles, underscores that experiencing social disconnection can mimic physical threats in how our brains and immune systems respond—magnifying the release of inflammatory agents. From an evolutionary standpoint, sustained isolation disrupts our primal need for social integration—leading to inflammation and a whole host of downstream consequences.
It's easy to downplay the loneliness problem. When former U.S. surgeon general Vivek Murthy warned of the dangers of social isolation and proposed solutions, no meaningful government interventions ensued. Likewise, when the U.K. government appointed a minister for loneliness in 2018, many likened the move to a Monty Python sketch rather than seeing it as a serious policy intervention.
But the medical, social and even political costs of growing social isolation mean that we can no longer afford to ignore it.
Some solutions are straightforward. Medical innovators are now addressing social isolation through practices like ' social prescribing '—wherein health professionals connect patients who are lonely with nonmedical community services, volunteer programs, exercise groups and arts activities to improve their well-being. Instead of writing prescriptions for pills, doctors can prescribe a free pass to a museum, an invitation to join a gardening club, or a support group for people facing similar struggles. A recent multiyear evaluation of nature-oriented social prescribing in the U.K. found that programs significantly helped participants reduce anxiety and improve happiness.
Other solutions are more systemic. When Pete Buttigieg ran for president in 2020, he laid out an agenda for ' belonging and healing '—emphasizing new funding and policies around mental health and addiction as well as national service to rebuild community institutions and promote environmental restoration. Leaders should propose scaling up 'belonging infrastructure'—transit, green spaces, cultural venues, and mental health centers—while expanding purpose-driven national service programs like Americorps and investing in local journalism through public grants or tax incentives to restore trusted information sources and restore important foundations of community life.
This should be a bipartisan cause. Conservatives and liberals alike have an opening to address the crisis by leveraging faith and veterans' groups–for example, granting tax incentives or small federal matches that could help churches, synagogues, and veterans' groups build mentoring initiatives, addiction recovery support and efforts to revitalize parks, libraries and civic spaces. There's also growing bipartisan recognition of the role of social media in the crisis. In tackling big tech's impact on youth, leaders across the ideological spectrum should push toward full algorithmic transparency, restrictions to exploitative design features, and mandates for robust digital well-being protections for children.
Like inflammation in the body, social isolation weakens our civic 'immune system,' fueling polarization and making us more susceptible to authoritarian impulses. But Hannah Arendt emphasized that the condition is reversible. By investing in the foundations of shared belonging, we can restore our adapt to adapt to the challenges we face—from wildfires to pandemics to misinformation. It's time to get serious about our healing.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Business Wire
19 minutes ago
- Business Wire
Cloudbreak Pharma Inc. Announces Positive Phase 2 Results for CBT-004 in Patients with Vascularized Pinguecula
IRVINE, Calif.--(BUSINESS WIRE)--Cloudbreak Pharma Inc. a clinical-stage ophthalmology company developing innovative therapies for ocular surface diseases, today announced positive topline results from its Phase 2 clinical trial evaluating CBT-004 ophthalmic solution in patients with vascularized pinguecula and associated conjunctival hyperemia. "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognize Share Key Phase 2 Results Primary Endpoint Achieved: Both investigated concentrations of CBT-004 demonstrated statistically significant improvements in conjunctival hyperemia compared to vehicle at Day 28, as assessed by an independent reading center using digital imaging. Rapid Onset and Sustained Efficacy: Significant improvements were observed as early as Day 7 with the highest investigated concentration CBT-004 , with benefits persisting through the 28-day treatment period. Significant Symptom Relief: Both CBT-004 concentrations showed statistically significant improvements in five common patient-reported symptoms including burning/stinging, itching, foreign body sensation, eye discomfort, and pain compared to vehicle. Excellent Safety Profile: No treatment-related adverse events were observed. Most adverse events were mild to moderate. No clinically meaningful changes in visual acuity or intraocular pressure were reported. Addressing a Significant Unmet Medical Need Vascularized pinguecula affects millions of Americans and represents a substantial unmet medical need in ophthalmology. This common, benign conjunctival growth can become problematic when it develops abnormal blood vessels and inflammation, which can lead to persistent redness, irritation, pain, and foreign body sensation. Current management options are limited, with many patients relying on off-label corticosteroids or surgical excision, both of which carry significant limitations and potential complications. Study Design and Results The multicenter, randomized, double-masked, vehicle-controlled Phase 2 study enrolled 88 adult patients with vascularized pinguecula and associated conjunctival hyperemia. Participants were randomized to receive one of two concentrations of CBT-004, or vehicle. The primary endpoint was the change from baseline in conjunctival hyperemia at Day 28, as measured by an independent reading center using standardized digital imaging protocols. Expert Commentary "There is a significant unmet need for patients suffering from symptomatic pinguecula, as current therapies are largely off-label and may carry safety concerns with long-term use," said Dr. John Hovanesian, Clinical Professor of Ophthalmology and recognized key opinion leader in anterior segment disease. "The results from this trial are exciting, as they demonstrate that a targeted, non- steroidal therapy can meaningfully improve both the clinical signs and symptoms that impact patients' quality of life." "As a principal investigator in this study, I was impressed by the consistency and magnitude of improvement in both objective redness and patient-reported discomfort with CBT-004," commented Dr. Sherif El-Harazi, Medical Director at Global Research Management. "The safety profile was excellent, and I believe this therapy could represent a meaningful advance for our patients with vascularized pinguecula." About CBT-004 CBT-004 is a novel, preservative-free topical ophthalmic solution containing a potent and selective inhibitor of vascular endothelial growth factor (VEGF) receptors and platelet-derived growth factor (PDGF) receptors. The formulation is specifically designed to reduce abnormal blood vessel growth and inflammation associated with vascularized pinguecula while minimizing potential ocular surface toxicity through its preservative- free composition. Next Steps and Regulatory Strategy Based on these positive Phase 2 results, Cloudbreak Pharma Inc. plans to advance CBT-004 into Phase 3 development and initiate discussions with the U.S. Food and Drug Administration (FDA) to establish the regulatory pathway toward potential approval. The company anticipates providing updates on Phase 3 study design and timing in the coming months. Market Opportunity The vascularized pinguecula market represents a significant commercial opportunity with limited therapeutic options. The prevalence of pinguecula increases with age and UV exposure, affecting a substantial portion of the aging population. With no FDA-approved treatments specifically indicated for this condition, CBT-004 has the potential to become a category-defining therapy in this underserved market. About Cloudbreak Pharma Inc. Cloudbreak Pharma Inc. is a clinical-stage ophthalmology company dedicated to developing innovative therapies for ocular surface diseases with high unmet medical need. The company's pipeline focuses on novel treatments targeting inflammation, vascularization, and other pathological processes affecting the ocular surface. Cloudbreak is committed to improving outcomes for patients with challenging eye conditions through scientifically-driven therapeutic development. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding the potential therapeutic benefits of CBT-004, the company's clinical development plans, regulatory strategy, and market opportunity. These forward-looking statements are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause actual results to differ include, but are not limited to, the uncertainty of clinical trial results, regulatory approval processes, competitive developments, and other risks detailed in the company's filings. The company undertakes no obligation to update these forward-looking statements except as required by law. Please note that the information contained in this press release may not be complete. For further details about Cloudbreak Pharma Inc., and our drug candidates, please refer to our company's website (at


New York Post
2 hours ago
- New York Post
Trump, Xi may meet ahead of or during APEC summit October: report
President Trump might visit China before going to the Asia-Pacific Economic Cooperation summit between Oct. 30 and Nov. 1, or he could meet Chinese President Xi Jinping on the sidelines of the APEC event in South Korea, the South China Morning Post reported on Sunday, citing multiple sources. The two countries have been trying to negotiate an end to an escalating tit-for-tat tariff war that has upended global trade and supply chains. The two sides have discussed a potential meeting between the leaders in the region this year, but they have not confirmed a date or location yet, according to a person familiar with the matter. President Trump and Chinese President Xi Jinping in 2019. REUTERS Trump has sought to impose tariffs on US importers for virtually all foreign goods, which he says will stimulate domestic manufacturing and which critics say will make many consumer goods more expensive for Americans. He has called for a universal base tariff rate of 10% on goods imported from all countries, with higher rates for imports from the most 'problematic' ones, including China: imports from there now have the highest tariff rate of 55%. Trump has set a deadline of Aug. 12 for the US and China to reach a durable tariffs agreement. President Donald Trump has set a deadline of Aug. 12 for the US and China to reach a durable tariffs deal. Costfoto/NurPhoto/Shutterstock A spokesperson for Trump did not respond to a request for comment about the reported plans for a meeting with Xi in the autumn. The two countries' most recent high-level meeting was on July 11, when Secretary of State Marco Rubio and Chinese Foreign Minister Wang Yi had what both described as a productive and positive meeting in Malaysia about how trade negotiations should proceed. Rubio said then that Trump had been invited to China to meet with Xi, and said that both leaders 'want it to happen.' On Friday, China Commerce Minister Wang Wentao said China wants to bring its trade ties with the US back to a stable footing and that recent talks in Europe showed there was no need for a tariff war.


The Hill
3 hours ago
- The Hill
Majority oppose the way Trump is using detention facilities: CBS poll
A majority of Americans oppose the way President Trump is using migrant detention facilities amid his broader crackdown on immigration, according to a new CBS News/YouGov poll. When asked in the survey if they 'favor or oppose the way the Trump administration is using detention facilities to hold people it may try to deport,' 42 percent said they back it, while 58 percent were against. Republicans' 'big, beautiful bill' passed earlier this month included billions of dollars to ramp up what was already significantly increased immigration enforcement under Trump. The administration and Florida leaders recently came together to build a detention facility on a remote site in the Everglades to hold migrants waiting on deportation. The site, dubbed 'Alligator Alcatraz,' opened earlier this month, featuring soft-sided holding units for hundreds of detainees via a partnership in which the federal government would provide funding and the Florida Division of Emergency Management (FDEM) would oversee the build-outs as well as management. Last week, Homeland Security Secretary Kristi Noem defended conditions at the facility after Democrats said the detained migrants faced 'inhumane' treatment there. 'Our detention centers at the federal level are held to a higher standard than most local or state centers and even federal prisons. The standards are extremely high,' Noem said on NBC's 'Meet the Press' at the time. In the CBS News/YouGov poll, 53 percent said 'the way Donald Trump and the Republicans are handling immigration' is 'too tough,' while 18 percent said it is 'not tough enough' and 29 percent called it 'about right.' Majorities say the administration is deporting more people than they though they would, and also that officials are not prioritizing dangerous criminals. The survey took place from July 16 to 18, featuring 2,343 people and a margin of error of about plus or minus 2.5 percentage points.